| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2023 | Outperform | Evercore ISI | |
| 10/10/2023 | $29.00 | Buy | Truist |
| 10/10/2023 | $35.00 | Buy | Jefferies |
| 10/10/2023 | $30.00 | Overweight | JP Morgan |
| 10/6/2023 | Outperform | William Blair |
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Tim Van Hauwermeiren to its board of directors. As co-founder and CEO of argenx, Tim has built a reputation for his strong execution and innovation, leading argenx from early-stage development into a global immunology company. "RayzeBio has the potential to transform the oncology treatment landscape through targeted radiopharmaceuticals. I see a lot of parallels between RayzeBio and argenx and look forward to leveraging my experience to help RayzeBio unlock the full pote
SC 13G/A - RayzeBio, Inc. (0001825367) (Subject)
Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State-of-the-Art Radiopharmaceutical Manufacturing Capabilities Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per shar
15-12G - RayzeBio, Inc. (0001825367) (Filer)
S-8 POS - RayzeBio, Inc. (0001825367) (Filer)
8-K - RayzeBio, Inc. (0001825367) (Filer)
25-NSE - RayzeBio, Inc. (0001825367) (Subject)
SC 14D9/A - RayzeBio, Inc. (0001825367) (Subject)
SC TO-T/A - RayzeBio, Inc. (0001825367) (Subject)
Evercore ISI initiated coverage of RayzeBio with a rating of Outperform
Truist initiated coverage of RayzeBio with a rating of Buy and set a new price target of $29.00
Jefferies initiated coverage of RayzeBio with a rating of Buy and set a new price target of $35.00
JP Morgan initiated coverage of RayzeBio with a rating of Overweight and set a new price target of $30.00
William Blair initiated coverage of RayzeBio with a rating of Outperform
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
4 - RayzeBio, Inc. (0001825367) (Issuer)
-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent
- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo
Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey
Bristol Myers Squibb (NYSE:BMY) today announced that its previously announced tender offer (the "Offer") to acquire all of the outstanding shares of RayzeBio, Inc. (NASDAQ:RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024 (the "Expiration Time"). Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, approximately 53,052,499 shares of RazyeBio common stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 86% of the issued and outstanding shares of RayzeBio common stock at th
Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb's previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting period occurred at 11:59 p.m. EST on February 9, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240211117969/en/ Expiration of the waiting period under the HSR Act satisfies one of th
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State of the Art Radiopharmaceutical Manufacturing Capabilities PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which
Transaction Brings RayzeBio's Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb's Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neuroendocrine Tumors and Early-stage Development for Treatment of Small Cell Lung Cancer and Potentially Other Tumor Types Gains Robust IND Engine and State-of-the-Art Radiopharmaceutical Manufacturing Capabilities Bristol Myers Squibb (NYSE:BMY) and RayzeBio, Inc. (NASDAQ:RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per shar
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives. "We have made significant progress in 2023 and achieved several clinical, discovery and corporate milestones as we continue to lead innovation in developing targeted radiopharmaceuticals for the benefit of patients with cancer," said Ken Song, M.D., President and CEO of RayzeBio. "Our lead asset, RYZ101, is the first Actinium-225 based treatment in a Phase 3 clinical trial.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company's management team will participate in the following investor conferences in November 2023: Truist Securities BioPharma Symposium: Panel discussion on Wednesday, November 8 at 10:45 a.m. ET in New York.Jefferies London Healthcare Conference: Presentation on Wednesday, November 15 at 12:00 p.m. GMT (7:00 a.m. ET) in London, England.Evercore ISI HealthCONx Conference: Fireside chat on Thursday, November 30 at 10:00 a.m. ET in Miami. RayzeBio will also be participati
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (NASDAQ:RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the appointment of Tim Van Hauwermeiren to its board of directors. As co-founder and CEO of argenx, Tim has built a reputation for his strong execution and innovation, leading argenx from early-stage development into a global immunology company. "RayzeBio has the potential to transform the oncology treatment landscape through targeted radiopharmaceuticals. I see a lot of parallels between RayzeBio and argenx and look forward to leveraging my experience to help RayzeBio unlock the full pote
Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash plus a non-transferable contingent value right (CVR) of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone. The upfront cash portion of the consideration represents a transaction value of approximately $2 billion, a 97% premium to Fusion’s closing market price of $10.64 on March 18, 2024. Related Content: Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Says AstraZeneca Is Favorably Positioned. Combined, the upfront and maximum potential contingent value payments represent, if achie
Jim Cramer said WK Kellogg Co (NYSE:KLG) doesn’t have a "lot of growth, and it doesn’t have a lot of yield." He prefers Kellanova (NYSE:K) to that one. Recall how, in September, Kellogg split into two independently traded companies. The global snacking business was formed into Kellanova and the North American cereal brand became WK Kellogg. When asked about Lithia Motors, Inc. (NYSE:LAD), Cramer said, "I like CarMax, Inc. (NYSE:KMX), they're magnificent, and then I like Lithia." The "Mad Money" host also said he doesn’t recommend the tobacco companies, when asked about Altria Group, Inc. (NYSE:MO). When asked about Citigroup Inc. (NYSE:C), he said, "I say ix-nay Citi-nay. I
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Deal volume fell 9% from 242 deals in Q2 2023 to 221 M&A deals in Q3 2023. PricewaterhouseCoopers wrote in its Pharmaceutical and Life Sciences: U.S. Deals 2024 Outlook. "As regulators' perspectives on key deal factors become better understood, there may be a return of larger deals, along with continued interest in the $5 billion to $15 billion deals to fill targeted strategic gaps." "Despite some stabilization in the macroeconomic environment and the potential for a soft landing in sight, continued geopolitical and regulatory uncertainty
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ:FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE:BMY) has agreed to acquire RayzeBio Inc (NASDAQ:RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. On Wednesda
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday. U.S. stocks closed higher on Tuesday, with the S&P 500 moving closer to record levels. The index is less than 1% down from its record closing high of 4,796.56 notched in January 2022. US stocks also closed higher last week, with the S&P 500 recording its eighth straight weekly surge. On the economic data front, the Chicago Fed National Activity Index increased to +0.03 in November versus a revised reading of -0.66 in the prior month. The S&P CoreLogic Case-Shiller 20-city home price index rose by 4.9% year-over-year in October, recording the la
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The S&P 500 also rose, gaining, 0.45% to 4,776.17. Check This Out: Top 3 Tech And Telecom Stocks That Could Blast Off In December Leading and Lagging Sectors Energy shares jumped by 1.3% on Tuesday. In trading on Tuesday, health care shares fell by 0.01%. Top Headline The FHFA house price index rose by 0.3% from the prior month in October. Equities Trading UP Gracell Biotechnologies Inc. (NASDAQ:GRCL) shares shot up 60% to $9.91. AstraZeneca Plc (NASDAQ:AZN) agreed to acquire
Shares of RayzeBio, Inc. (NASDAQ:RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion. RayzeBio shares gained 100% to $61.38 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers ARB IOT Group Limited (NASDAQ:ARBB) shares rose 270% to $3.4850 after gaining around 18% on Friday. IMAC Holdings, Inc. (NASDAQ:BACK) shares jumped 108% to $5.05 after jumping 53% on Friday. Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) jumped 75% to $2.0988 after the company announced 95% accuracy results for HYLA blood sensor. Gracell Biotechnologi
Gainers RayzeBio (NASDAQ:RYZB) stock moved upwards by 100.8% to $61.4 during Tuesday's regular session. The market value of their outstanding shares is at $3.6 billion. IMAC Hldgs (NASDAQ:BACK) stock moved upwards by 74.02% to $4.21. The company's market cap stands at $4.7 million. Gracell Biotechnologies (NASDAQ:GRCL) shares increased by 59.93% to $9.9. The company's market cap stands at $949.6 million. Sight Sciences (NASDAQ:SGHT) stock rose 44.61% to $5.26. The market value of their outstanding shares is at $256.6 million. 60 Degrees (NASDAQ:SXTP) shares moved upwards by 44.17% to $1.3. The market value of their outstanding shares is at $7.5 million. Science 37 Hldgs (NASDAQ:SNCE) s
William Blair analyst Andy Hsieh downgrades RayzeBio (NASDAQ:RYZB) from Outperform to Market Perform.